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INTRODUCTION
Women tend to experience worse clinical outcomes than men 
after undergoing contemporary interventional therapies.1-3 
Poorer clinical outcomes in women may be because women 
have higher risk profiles for delayed onset of disease, older age, 
smaller body surface area, and comorbidities at the time of 
clinical presentation of coronary artery disease.1-3 In addition, 
women reportedly exhibit higher procedural risk than men ac-
cording to the National Cardiovascular Data Registry4 and a 
lower revascularization rate of lesions with chronic total occlu-
sion (CTO) after coronary artery bypass graft surgery, based on 
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the Canadian Multicenter CTO Registry.5 However, other stud-
ies have shown that after adjusting for confounding risk factors, 
sex-specific risk was limited, and adjusted rates of adverse car-
diac events, including long-term mortality and revasculariza-
tion, were similar between women and men.1-3 Accordingly, al-
though sex differences may exist in a high-risk subset of 
coronary artery disease patients, sex-specific clinical outcomes 
have not been well established, partly because of the small sam-
ple of women in prospective trials.
Compared to men, women have smaller vessels,6-8 and a small-
er target vessel size has been shown to be associated with a 
greater likelihood of target lesion revascularization.9 Mean-
while, however, women reportedly show a similar rate of target 
lesion revascularization after stent implantation, compared to 
men, despite smaller vessel sizes.1 Although differences in body 
size and clinical risk factors may explain this paradoxical find-
ing, detailed associations among sex, anthropometric measure-
ments, and procedural/clinical outcomes after percutaneous 
coronary intervention (PCI) have not yet been established.
In this study, we sought to investigate the effects of sex and 
anthropometric measurements on clinical outcomes after next-
generation drug-eluting stent (DES) implantation for complex 




Patients were identified from three randomized trials: REal 
Safety and Efficacy of 3-month dual antiplatelet Therapy fol-
lowing Endeavor zotarolimus-eluting stent implantation (RE-
SET),10,11 Impact of intraVascular UltraSound guidance on out-
comes of Xience Prime stents in Long lesions (IVUS-XPL),12 
and Chronic Total Occlusion InterVention with drUg-eluting 
Stents (CTO-IVUS).13 Unique identifiers of Clinical Trial Regis-
tration-URL: http://www.clinicaltrials.gov were as follows: 
NCT01145079 for RESET, NCT01308281 for IVUS-XPL, and 
NCT01563952 for CTO-IVUS. Briefly, the RESET trial tested the 
non-inferiority of 3-month dual antiplatelet therapy following 
Endeavor sprint zotarolimus-eluting stent (Medtronic Inc., 
Santa Rosa, CA, USA) implantation, compared with 12-month 
dual antiplatelet therapy after implantation of another avail-
able DES. In the pre-specified long lesion subset of this study, 
543 patients were randomly assigned to either IVUS- or angi-
ography-guided DES implantation groups.11 The IVUS-XPL tri-
al investigated the usefulness of IVUS guidance during everoli-
mus-eluting stent (Xience prime, Abbott Vascular, Santa Clara, 
CA, USA) implantation for long coronary lesions. A total of 
1400 patients were randomly assigned to receive either IVUS- 
or angiography-guided stent implantation. The CTO-IVUS trial 
was undertaken to test the hypothesis that IVUS-guided CTO 
intervention would be superior to angiography-guided inter-
vention. Four hundred two patients with CTO lesions were ran-
domized to either IVUS- or angiography-guided intervention. 
Detailed protocols of these trials have been published previous-
ly.10-13 The study protocols of these trials were approved by the 
Institutional Review Board of each participating institution, and 
written consent was obtained from all patients.
Of 1129 patients (333 women and 796 men) who underwent 
IVUS-guided intervention, women were older than men. In ad-
dition, there were significant differences in the frequencies of 
hypertension, dyslipidemia, current smoking, multi-vessel dis-
ease, and CTO lesions between women and men (Supplemen-
tary Table 1, only online). Accordingly, we performed propensi-
ty score matching to adjust for significant differences in clinical 
and angiographic characteristics in the women and men. After 
matching propensity scores for 333 women and 796 men, 333 
matched pairs were selected for analysis.
Stent implantation
Next-generation DESs composed of everolimus-, zotarolimus-, 
and biolimus-eluting stents were implanted according to stan-
dard techniques. If a lesion could not be covered with a single 
stent, overlapping stents were used. Stent diameter and length 
were based on online IVUS measurements. Adjunct high-pres-
sure dilation was performed at the discretion of the operators, 
based on the IVUS findings. Although IVUS could be performed 
at any step of DES implantation, post-intervention IVUS exami-
nation was mandatory.11-13 One of two commercially available 
IVUS systems [Atlantis or I-Lab (Boston Scientific Corp/SCIMED, 
Minneapolis, MN, USA) or Eagle Eye (Volcano Therapeutics, 
Rancho Cordova, CA, USA)] was used.
Pre-PCI, all patients received at least 75 mg of aspirin. A load-
ing dose of 300 mg of clopidogrel was administered at least 12 
hours pre-PCI.10-13 However, if the loading dose of clopidogrel 
was not administered 12 hours in advance, the patient received 
a 600 mg loading dose of clopidogrel in the catheterization lab-
oratory prior to PCI.10-12 Unfractionated heparin was adminis-
tered to maintain an activated clotting time >250 seconds. Use 
of glycoprotein IIb/IIIa inhibitors was left to the operator’s dis-
cretion. After stent implantation, aspirin (100 mg, daily) was pre-
scribed indefinitely; the duration of clopidogrel administration 
(75 mg, daily) depended on the randomized assignments in the 
RESET and IVUS-XPL trials.11-12 In the CTO-IVUS trial, clopido-
grel was used for at least 12 months.13
Anthropometry
At the time of the index procedure, height and body weight 
were measured using a digital scale in all patients. Body surface 
area (m2) was calculated using the Mosteller formula: √[weight 
(kg)×height (cm)/3600],14 and body mass index (kg/m2) was 
calculated from the following formula: weight (kg)/[height 
(m)]2. Lean body mass (kg) was calculated using the James for-
mula as follows: [1.1×weight (kg)]-{128×[weight (kg)/height 
(cm)]2} for men; [1.07×weight (kg)]-{148×[weight (kg)/height 
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(cm)]2} for women.15 Fat mass (kg) was calculated as lean body 
mass subtracted from body weight.
Angiographic and IVUS evaluation
Angiographic and IVUS measurements were performed by an-
alysts who were blinded to patient information and treatment 
assignments in an independent core laboratory at the Cardio-
vascular Research Center, Seoul, Korea. Quantitative coronary 
angiography analysis was performed using an off-line quantita-
tive coronary angiographic system [Cardiovascular Angio-
graphic Analysis System (CAAS), Pie Medical Instruments, 
Maastricht, the Netherlands]. Using a guiding catheter for mag-
nification-calibration, the diameters of reference vessels (the 
average of the proximal and distal reference lumen diameters), 
the minimal luminal diameter, and the percent diameter steno-
sis were measured before and after DES implantation from dia-
stolic frames in a single, matched view showing the smallest 
minimal luminal diameter.
Standardized planimetry of the lumen, stent, and vessel cross-
sectional area was performed using planimetry software (Echo-
plaque, INDEC Systems, Santa Clara, CA, USA) in accordance 
with the IVUS guidelines of the American College of Cardiolo-
gy.16 Target lesions and both proximal and distal reference seg-
ments were assessed quantitatively. The post-intervention tar-
get lesion site was the image slice with the minimal lumen area 
(MLA). Proximal and distal reference segments were the most 
normal-looking segments within 5 mm proximal and distal to 
the target lesion.
Clinical outcomes and follow-up 
Post-PCI clinical assessments were performed in-hospital and 
at 1, 3, 6, and 12 months after discharge either by clinic visit or 
telephone interview. Clinical events were defined according to 
the Academic Research Consortium.17 All deaths were consid-
ered cardiac deaths unless a definite non-cardiac cause could 
be established.17 Target lesion-related myocardial infarction 
during the 1-year follow-up after hospital discharge was de-
fined as the presence of clinical symptoms, electrocardiographic 
changes, or abnormal imaging findings of myocardial infarction, 
combined with an increase in the creatine kinase myocardial 
band fraction above the upper normal limits or an increase in 
troponin-T/troponin-I to greater than the 99th percentile of the 
upper normal limit. The territory of the myocardial infarction 
was supplied by the coronary artery containing the stented le-
sions.12,17 Ischemia-driven target lesion revascularization was 
defined as a repeat PCI or bypass surgery of the target lesion 
with either of the following: 1) angiographic diameter stenosis 
≥50% by quantitative coronary angiographic analysis with docu-
mented evidence of a positive stress test or 2) angiographic di-
ameter stenosis ≥70% irrespective of documented evidence of a 
positive stress test.17
Statistical analysis
Statistical analysis was performed using SPSS (version 18.0.0, 
SPSS Inc., Chicago, IL, USA) and R (version 2.8.0, R Foundation 
for Statistical Computing, Vienna, Austria) software. Propensity 
scores were estimated by fitting a logistic regression model us-
ing the following variables for women and men: age, hyperten-
sion, diabetes mellitus, dyslipidemia, current smoking, clinical 
presentation of acute myocardial infarction, angiographic multi-
vessel disease, and lesions with CTO. Propensity score match-
ing was performed using nearest neighbor matching without 
calipers. The Hansen and Bowers balance test p-value was 0.913, 
indicating good covariate balance. The C-statistic for the model 
was 0.567. Categorical variables are reported as numbers and 
percentages and were compared using the χ2 test or Fisher’s ex-
act test. Continuous variables are reported as means±standard 
deviations or medians (interquartile ranges). Differences be-
tween women and men were analyzed with Student’s t test or 
the Mann-Whitney U test (if data were skewed), and those 
among the tertiles of patients’ height were analyzed by one-way 
analysis of variance or the Kruskal-Wallis test (if data were 
skewed). Adverse cardiac events at 12 months were compared 
using Cox’s regression analysis stratified by enrolled trials. To 
determine independent predictors of adverse cardiac events, 
multivariable Cox’s regression analysis with a stepwise method 
was performed and stratified by trials. Multivariable linear re-
gression model using a stepwise method was applied to evalu-
ate associations between anthropometric measurements and 
post-intervention MLA as assessed by IVUS. All p-values were 
two-sided, and a p-value <0.05 was considered statistically sig-
nificant.
RESULTS
Table 1 shows the clinical, procedural, and IVUS characteristics 
of the 666 patients who were matched by propensity scores. 
Compared to men, women were shorter in stature, weighed 
less, and had a smaller body surface area and lower lean body 
mass. Fat mass, however, was greater in women than in men. 
Body mass index was not different between women and men. 
Pre- and post-intervention reference vessel diameters by quan-
titative coronary angiographic analysis were smaller in women. 
In post-intervention IVUS analysis, MLA at the target lesions, as 
well as the lumen and external reference membrane area at the 
proximal and distal reference segments, were also significantly 
smaller in women than men.
PCI-related outcomes at 12 months are shown in Table 2. The 
incidence of adverse cardiac events, including cardiac death, 
target lesion-related myocardial infarction, and ischemia-driv-
en target lesion revascularization, was not significantly different 
between women and men. The only significant predictor of ad-
verse cardiac events was post-intervention MLA by IVUS [haz-
ard ratio (HR)=0.620, 95% confidence interval (CI)=0.423–0.909, 
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Table 1. Baseline, Procedural, and IVUS Characteristics by Sex
Women (n=333) Men (n=333) p value
Age (yrs) 67.2±8.0 66.4±8.0 0.222
Height (cm) 154.2±5.3 166.8±6.1 <0.001
Weight (kg) 58.4±8.1 68.3±9.1 <0.001
Body surface area (m2) 1.6±0.1 1.8±0.1 <0.001
Body mass index (kg/m2) 24.6±3.3 24.5±2.7 0.667
Lean body mass (kg) 40.9±3.4 53.5±5.4 <0.001
Fat mass (kg) 17.5±5.3 14.8±4.1 <0.001
Hypertension 235 (70.6) 227 (68.2) 0.501
Diabetes mellitus 126 (37.8) 123 (36.9) 0.810
Dyslipidemia 247 (74.2) 237 (71.2) 0.385
Current smoker 9 (2.7) 12 (3.6) 0.506
Clinical diagnosis 0.689
Stable angina 197 (59.2) 186 (55.9)
Unstable angina 110 (33.0) 119 (35.7)
Acute myocardial infarction 26 (7.8) 28 (8.4)
Multi-vessel disease 201 (60.4) 209 (62.8) 0.524
Multi-vessel stent implantation 88 (26.4) 80 (24.0) 0.475
Chronic total occlusion 37 (11.1) 40 (12.0) 0.716
Duration of dual anti-platelet therapy (months) 12.0 (6.0, 12.0) 9.6 (6.0, 12.0) 0.626
Coronary arteries 0.728
Left anterior descending artery 224 (67.3) 215 (64.6)
Left circumflex artery 44 (13.2) 50 (15.0)
Right coronary artery 65 (19.5) 68 (20.4)
Quantitative angiography analysis
Pre-intervention
Reference vessel diameter (mm) 2.8±0.4 2.9±0.5 0.038
Minimum lumen diameter (mm) 0.8±0.5 0.8±0.5 0.109
Diameter stenosis (%) 70.6±16.1 73.6±15.9 0.020
Lesion length (mm) 33.8±11.3 34.1±12.4 0.705
Post-intervention
Reference vessel diameter (mm) 2.9±0.4 3.0±0.5 0.008
Minimum lumen diameter (mm) 2.5±0.4 2.6±0.4 <0.001
Diameter stenosis (%) 12.5±8.4 12.0±9.2 0.491
Stent type 0.656
Everolimus-eluting stent 250 (75.1) 260 (78.1)
Zotarolimus-eluting stent 63 (18.9) 55 (16.5)
Biolimus-eluting stent 20 (6.0) 18 (5.4)
Stent overlap 112 (33.6) 107 (32.1) 0.680
Stent diameter (mm) 3.0±0.3 3.1±0.4 <0.001
Stent length (mm) 39.6±13.9 39.5±14.3 0.932
Adjunct post-dilation 235 (70.6) 225 (67.6) 0.402
Final balloon size (mm) 3.0±0.4 3.1±0.4 0.023
Maximal inflation pressure (atm) 17.3±3.9 16.3±3.8 0.009
Post-intervention IVUS analysis
Proximal reference segment EEM area (mm2) 15.9±4.4 18.2±5.3 <0.001
Proximal reference segment lumen area (mm2) 8.4±2.8 9.0±3.4 0.017
Minimum lumen area (mm2) 5.3±1.6 5.8±1.8 0.002
Distal reference segment EEM area (mm2) 9.0±3.4 10.5±4.3 <0.001
Distal reference segment lumen area (mm2) 5.8±1.8 6.3±2.2 0.004
IVUS, intravascular ultrasound; EEM, external elastic membrane.
Data are presented as n (%), means±SD, or medians (interquartile ranges).
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p=0.014], not female sex (Supplementary Table 2 and 3, only 
online).
Fig. 1 shows the associations between anthropometric mea-
surements and post-intervention MLA evaluated by IVUS. 
While height, weight, body surface area, and lean body mass 
were significantly associated with post-intervention MLA, body 
mass index, and fat mass were not. The final multivariable linear 
regression analysis revealed that height (coefficient=0.041, 95% 
CI=0.025–0.057, p<0.001) and CTO lesions (coefficient=-0.622, 
95% CI=-1.077–-0.167, p=0.008) were independently associated 
with post-intervention MLA as assessed by IVUS (Supplemen-
tary Table 4, only online).
Clinical, procedural, and IVUS characteristics were compared 
according to tertiles of patient height, as shown in Table 3. Com-
pared to the intermediate or high tertile patients, those in the 
low tertile of height were older and mostly female. Although their 
weight, body surface area, and lean body mass were the small-
est, patients in the low tertile of height had a greater body mass 
index and fat mass than intermediate or high tertile patients. 
Post-intervention IVUS showed that the external elastic mem-
brane and lumen area of the reference segment, as well as a 
MLA of target lesions, were smallest in patients in the low tertile 
of height. In an adjusted (age and sex) model, patients in the 
low tertile of height were at greater risk for adverse cardiac 
events at 12 months than those in the high tertile of height 
(HR=6.391, 95% CI=1.160–35.206, p=0.033) (Fig. 2).
DISCUSSION
In this IVUS study, sex was not independently associated with 
adverse cardiac events at 12 months after next-generation DES 
implantation for lesions with long stenosis or CTO. After next-
generation DES implantation, the only significant predictor of 
adverse cardiac events was post-intervention MLA as evaluated 
by IVUS. Although women had smaller-sized reference vessels 
and post-intervention MLA than men, independent factors that 
affected post-intervention MLA were height and CTO lesions. 
Compared to patients in the high tertile of height, those in the 
low tertile of height were at greater risk of adverse cardiac events 
at 12 months.
Compared to men, women have smaller coronary arteries, 
regardless of body surface area.6-8 These findings were based on 
angiography and autopsy,6,7 and a previous IVUS study also 
demonstrated the presence of these characteristics, explaining 
the increased susceptibility of women to vessel occlusion.8 How-
ever, despite the intrinsic effect of sex on coronary dimensions, 
little is known about sex differences in clinical outcomes, such 
as mortality or target lesion revascularization.1-3 In the present 
study, we evaluated complex lesions based on the hypothesis 
that adverse cardiac events could differ significantly in inci-
dence between males and females. Similar to previous stud-
ies,6-8 we found that the vessel size of lesions with long stenosis 
or CTO was smaller in women than in men, and this feature of 
women was consequently associated with a smaller post-inter-
vention MLA of the target lesion. However, sex was not associ-
ated with adverse clinical outcomes at 12 months post-inter-
vention, and furthermore, its associations with post-intervention 
MLA were attenuated after adjusting for anthropometric vari-
ables. Accordingly, our results suggest that there is no sex-spe-
cific risk for procedural or clinical outcomes in coronary artery 
disease patients with complex lesions.
Previous cohort studies have consistently shown that over-
weight or obese patients with coronary artery disease exhibit 
better survival and lower cardiovascular events than normal 
weight patients.18-20 However, it is controversial whether this 
obesity paradox is a real phenomenon, and the mechanisms 
responsible for this reversed association are still unknown.18-20 
Recently, an IVUS study suggested that a high body mass index 
was associated with a larger post-intervention stent area.21 How-
ever, confounders were not fully adjusted for, and other anthro-
pometric variables, with the exception of body mass index, 
were not evaluated.21 In the present study, height, weight, body 
surface area, and lean body mass were associated with post-in-
tervention MLA; body mass index and fat mass were not. Thus, 
tall and heavier patients might have a larger MLA after PCI than 
short and relatively thin patients, despite similar body mass in-
dexes. Because height and weight contribute to body mass in-
dex in opposite ways, the lack of association between body mass 
index and post-intervention MLA suggests that a more impor-
tant determinant of cardiovascular risk based on body mass in-
dex may be height, rather than weight.22 In addition, the present 
study suggests that body mass index does not reflect obesity ac-
curately, because it did not differentiate lean mass from body 
fat. This finding is consistent with the suggestion of a previous 
study,18 and raises the question of whether body mass index is 
truly associated with cardiovascular events. Most previous stud-
ies have only used body mass index as a measure of obesity.18
Among the anthropometric variables measured in this study, 
height was most closely correlated to post-intervention MLA, 
Table 2. Adverse Cardiac Events at 12 Months
Women (n=333) Men (n=333) Hazard ratio (95% confidence interval) p value
Adverse cardiac events 8 (2.4) 8 (2.4) 1.039 (0.390–2.769) 0.939
Cardiac death* 0 (0) 2 (0.6) - 0.499
Target lesion–related myocardial infarction* 0 (0) 2 (0.6) - 0.499
Ischemia-driven target lesion revascularization 8 (2.4) 6 (1.8) 1.381 (0.479–3.982) 0.551
*Categorical variables were compared with Fisher’s exact test (for 2-way comparisons).
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Fig. 1. Associations among anthropometric measurements and post-intervention minimum lumen area (MLA) as evaluated by intravascular ultrasound. 
While height, weight, body surface area, and lean body mass were significantly associated with post-intervention MLA, body mass index and fat mass 
were not. Black dots indicate women and white dots indicate men.
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Table 3. Baseline, Procedural, and IVUS Characteristics According to Height Tertile
Height
p value
Low (n = 213) Intermediate (n = 220) High (n = 233)
Age (yrs) 68.0±7.9 66.8±7.8 65.7±8.1 0.011
Men 12 (5.6) 101 (45.9) 220 (94.4) <0.001
Height (cm) 150.9±3.6 159.9±2.6 170.0±4.0 <0.001
Weight (kg) 57.1±7.8 61.9±8.0 70.6±8.8 <0.001
Body surface area (m2) 1.5±0.1 1.7±0.1 1.8±0.1 <0.001
Body mass index (kg/m2) 25.1±3.3 24.2±3.0 24.4±2.7 0.009
Lean body mass (kg) 39.8±3.1 46.0±4.8 55.1±5.2 <0.001
Fat mass (kg) 17.3±5.3 15.9±5.2 15.4±4.2 <0.001
Hypertension 156 (73.2) 150 (68.2) 156 (67.0) 0.319
Diabetes mellitus 84 (39.4) 83 (37.7) 82 (35.2) 0.647
Dyslipidemia 151 (70.9) 161 (73.2) 172 (73.8) 0.770
Current smoker 6 (2.8) 5 (2.3) 10 (4.3) 0.443
Acute myocardial infarction 14 (6.6) 15 (6.8) 25 (10.7) 0.191
Multi-vessel disease 127 (59.6) 139 (63.2) 144 (61.8) 0.745
Multi-vessel stent implantation 56 (26.3) 57 (35.9) 55 (23.6) 0.776
Chronic total occlusion 28 (13.1) 24 (10.9) 25 (10.7) 0.680
Duration of dual anti-platelet therapy (months) 12.0 (6.0, 12.0) 12.0 (6.0, 12.0) 6.0 (6.0, 12.0) 0.298
Coronary arteries 0.366
Left anterior descending artery 148 (69.5) 141 (64.1) 150 (64.4)
Left circumflex artery 24 (11.3) 30 (13.6) 40 (17.2)
Right coronary artery 41 (19.2) 49 (22.3) 43 (18.4)
Quantitative angiography analysis
Pre-intervention
Reference vessel diameter (mm) 2.8±0.4 2.8±0.5 2.9±0.5 0.328
Minimum lumen diameter (mm) 0.8±0.5 0.8±0.5 0.8±0.5 0.720
Diameter stenosis (%) 71.5±16.5 71.5±15.8 73.3±15.8 0.402
Lesion length (mm) 34.7±12.0 32.5±11.1 34.6±12.5 0.096
Post-intervention
Reference vessel diameter (mm) 2.9±0.4 3.0±0.5 3.0±0.5 0.144
Minimum lumen diameter (mm) 2.5±0.3 2.6±0.4 2.6±0.4 0.005
Diameter stenosis (%) 12.4±8.9 11.4±8.6 12.9±8.9 0.195
Stent type 0.519
Everolimus-eluting stent 160 (75.1) 166 (75.5) 184 (79.0)
Zotarolimus-eluting stent 37 (17.4) 44 (20.0) 37 (15.9)
Biolimus-eluting stent 16 (7.5) 10 (4.5) 12 (5.2)
Stent overlap 76 (35.7) 67 (30.5) 76 (32.6) 0.509
Stent diameter (mm) 3.0±0.3 3.0±0.4 3.1±0.4 <0.001
Stent length (mm) 40.8±14.6 38.5±13.8 39.4±13.8 0.233
Adjunct post-dilation 142 (66.7) 161 (73.2) 157 (67.4) 0.269
Final balloon size (mm) 3.1±0.4 3.1±0.4 3.2±0.5 0.110
Maximal inflation pressure (atm) 17.3±4.0 16.6±4.1 16.5±3.5 0.176
Post-intervention IVUS analysis
Proximal reference segment EEM area (mm2) 16.1±4.4 16.6±4.9 18.3±5.5 <0.001
Proximal reference segment lumen area (mm2) 8.3±2.7 8.6±2.9 9.2±3.6 0.022
Minimum lumen area (mm2) 5.2±1.5 5.6±1.8 5.9±1.8 <0.001
Distal reference segment EEM area (mm2) 8.7±3.0 9.6±4.0 10.9±4.4 <0.001
Distal reference segment lumen area (mm2) 5.6±1.6 6.0±2.0 6.4±2.3 <0.001
IVUS, intravascular ultrasound; EEM, external elastic membrane.
Data are presented as n (%), means±SD, or medians (interquartile ranges).
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and patients with a short stature tended to have more adverse 
events after PCI than taller patients. Although negative and 
even controversial studies have been published, a meta-analy-
sis and two large population-based studies have shown an in-
verse association between height and coronary artery disease.23-25 
In the meta-analysis, the mean relative risk of cardiovascular 
morbidity and mortality was 1.46 in individuals in the shortest 
height category, compared to those in the tallest category, re-
gardless of sex.23 Although the mechanisms underlying this in-
verse association are unclear, a large study recently demon-
strated a significant association between height-associated 
single nucleotide polymorphisms and coronary artery disease.26 
This link was partly explained by the association between 
shorter height and adverse lipid profiles.26 In addition to biolog-
ical mechanisms, the theory of coronary vessel caliber may ex-
plain the inverse association between height and coronary ar-
tery disease. In the Coronary Artery Surgery Study (CASS), 
surgical mortality was inversely associated with the average di-
ameter of the grafted coronary arteries in both men and wom-
en.27 Similarly, the present study showed a close relationship 
between height and post-intervention MLA that was a predic-
tor for future adverse cardiac events.
Limitations
Our study may have been underpowered to compare the ef-
fects of sex and anthropometric measurements on PCI out-
comes because of the small sample size. Especially, the events 
of cardiac death or myocardial infarction rarely occurred, thus 
limiting the effects of sex on these outcomes. Because patients 
were drawn from the Korean population, the findings may not 
be generalizable to other ethnic groups. However, similar ten-
dencies to those observed in other ethnic groups regarding PCI 
outcomes and the obesity paradox have been reported in the 
Korean population.28-30 Lean body mass was not actually mea-
sured. Finally, the included trials’ heterogeneity, such as inclu-
sion/exclusion criteria and treatment strategies, may potentially 
affect the present results.
Conclusions
Sex was not found to be associated with post-intervention MLA 
as evaluated by IVUS and 12-month adverse cardiac events af-
ter next-generation DES implantation for lesions with long ste-
nosis or CTO. However, height independently affected the post-
intervention MLA of complex target lesions, and short stature 
may be associated with worse outcomes after PCI.
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